BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 16940798)

  • 21. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
    Daniel DB; Crawford J;
    Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
    Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with antibiotics in the treatment of febrile neutropenia in children.
    Riikonen P
    Stem Cells; 1995 May; 13(3):201-5. PubMed ID: 7613488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols.
    Dolan S; Crombez P; Munoz M
    Eur J Oncol Nurs; 2005; 9 Suppl 1():S14-23. PubMed ID: 16207534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegfilgrastim use during chemotherapy: current and future applications.
    Wolf T; Densmore JJ
    Curr Hematol Rep; 2004 Nov; 3(6):419-23. PubMed ID: 15496275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics.
    Wingard JR; Elmongy M
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):144-54. PubMed ID: 19237297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
    Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
    Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
    Watanabe T
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider.
    Lo N; Cullen M
    Hematol Oncol; 2006 Sep; 24(3):120-5. PubMed ID: 16783844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
    Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
    J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
    Page AV; Liles WC
    Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
    Saloustros E; Tryfonidis K; Georgoulias V
    Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
    Adams JR; Angelotta C; Bennett CL
    J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
    Shochat E; Rom-Kedar V
    Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.